Navigation Links
Ardea Biosciences Reports Recent Accomplishments and Second Quarter 2011 Financial Results
Date:8/5/2011

n patients with chronic gout who will receive allopurinol.  Given the low response rate typically observed with allopurinol and its well established side effect profile, we expect a substantial number of patients from these studies will be eligible to enroll directly into our Phase 3 studies.  
  • During the third quarter of 2011, we expect to report the results of an "End of Phase 2" meeting with the FDA for lesinurad.
  • Our next generation URAT1 inhibitor for gout, RDEA3170, has received regulatory approval for Phase 1 dosing, which we expect will commence in the third quarter of 2011.

  • Second Quarter and Year-to-Date 2011 Financial ResultsAs of June 30, 2011, we had $141.3 million in cash, cash equivalents and short-term investments and $1.7 million in receivables, compared to $80.6 million in cash, cash equivalents and short-term investments and $17.0 million in receivables as of December 31, 2010.

    The net increase in cash, cash equivalents and short-term investments in 2011 was due primarily to our public offering of common stock, which was completed in February 2011 and resulted in net proceeds to us of $78.1 million, and the receipt in January 2011 of a $15.0 million milestone payment under our global license agreement with Bayer HealthCare (Bayer).  These increases were partially offset by the use of cash to fund our clinical-stage programs, personnel costs and for other general corporate purposes.  The decrease in receivables in this period was due to the receipt of the $15.0 million milestone payment from Bayer.

    Revenues totaled $2.2 million and $3.9 million for the three and six months ended June 30, 2011, respectively, and $3.5 million and $6.8 million for the three and six months ended June 30, 2010, respectively.  The revenue earned in 2010 and 2011 was primarily from the recognition of a portion of the $35.0 million upfront, non-refundable license fee and reimbursement of third
    '/>"/>

    SOURCE Ardea Biosciences, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Ardea Biosciences to Present at Upcoming Investor Conferences
    2. Ardea Biosciences Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at 2011 American Society of Clinical Oncology Annual Meeting
    3. Ardea Biosciences Reports Recent Accomplishments and Announces First Quarter 2011 Financial Results
    4. Ardea Biosciences Reports Recent Accomplishments and Announces Fourth Quarter and Full-Year 2010 Financial Results
    5. Ardea Biosciences Announces Exercise in Full of Overallotment Option for Common Stock Offering
    6. Ardea Biosciences Prices Public Offering of Common Stock
    7. Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients
    8. Ardea Biosciences to Present at Two Upcoming Investor Conferences
    9. Ardea Biosciences Awarded a $733,438 Grant from the U.S. Government Under the Patient Protection and Affordable Care Act
    10. Ardea Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference
    11. Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/24/2014)... St. Louis, Missouri (PRWEB) December 23, 2014 ... and targeting Swiss biotechnology company, Syngenta, are in the ... for pretrial proceedings. The consolidated case is In Re: ... in the U.S. District Court for the District of ... litigation (MDL) has been handed over to U.S. District ...
    (Date:12/24/2014)... Texas (PRWEB) December 23, 2014 ... methyl mercaptan such as its definition, classification, ... presents product specification, manufacturing process, and product ... technology and applications. The analysis also covers ... marketing channels, industry development trend and proposals. ...
    (Date:12/24/2014)... Texas , Dec. 23, 2014 ... company focused on gynecologic disease, announced today that ... Schuler , Birchview Fund LLC and several Vermillion ... of unregistered shares of Vermillion,s common stock and ... stock in a private placement.  ...
    (Date:12/22/2014)... The Center for Professional Innovation ... training across the life sciences industry, has partnered with ... to provide the organization's members with discounted classroom courses, ... the more than 350 sessions across 80 course titles. ... when registering for a public course at ...
    Breaking Biology Technology:Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3
    ... NEW YORK, Oct. 16 Wall St. Network,s 3-Minute,Press ... Tracee Tolentino that,features in-depth interviews with public company executives ... show is designed to provide viewers with insight into ... growth., Shows air Monday through ...
    ... first-cycle,approval for a new molecular entity (NME) is ... average, according to a new analysis from,PAREXEL Consulting, ... PRXL ),and leading global life sciences consultancy serving ... PAREXEL Consulting,analysis, 60 percent of sales for newly-approved ...
    ... The future of how the world communicates, and ... from the same source: nanotechnology. According to a ... on Emerging Nanotechnologies (PEN), nanotechnology will be central ... "green" energy technologies. , In the latest ...
    Cached Biology Technology:[video] Wall St. Network's 3-Minute Press Show Features Executive Interviews and Highlights Recent Press for the Following: IMMU, KYUS 2PAREXEL Consulting Quantifies Speed to Market: First-Cycle Approval for NME Produces $640 Million in Incremental Revenue on Average 2PAREXEL Consulting Quantifies Speed to Market: First-Cycle Approval for NME Produces $640 Million in Incremental Revenue on Average 3PAREXEL Consulting Quantifies Speed to Market: First-Cycle Approval for NME Produces $640 Million in Incremental Revenue on Average 4PAREXEL Consulting Quantifies Speed to Market: First-Cycle Approval for NME Produces $640 Million in Incremental Revenue on Average 5
    (Date:12/11/2014)... Minn. , Dec. 10, 2014  Data ... physiologic monitoring, has released a new series of ... of preclinical toxicology researchers. M series, part of ... toxicologists collect the best possible physiologic data when ... Adding functional endpoints to toxicology studies has ...
    (Date:12/10/2014)... N.C. , Dec. 9, 2014  Valencell, a ... it is seeing a staggering demand from its licensees ... the Company revealed, is not solely coming from fitness ... as well. "A wearable is only as ... result, accuracy is the ultimate driver in long-term mass ...
    (Date:12/10/2014)... SAN DIEGO , Dec. 9, 2014 ... and collaboration catalyst that provides the connective tissue that ... by enabling them to easily share client-level information; earned ... Foundation to expand to organizations serving seniors aging in ... San Diego" partner on December 11 th 4-6p. ...
    Breaking Biology News(10 mins):New telemetry implants expected to change how large animal toxicology studies are conducted 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4
    ... URBANA The University of Illinois scientists who ... cancer have developed a tool that will help them ... body. And they,ve secured funding from the National Institutes ... carotenoidsthe pigments that give the red, yellow, and orange ...
    ... the New York Academy of Sciences on December 9 ... science and policy initiatives addressing the global and national ... The Global Obesity Epidemic, is presented by the Academy ... with support from the new Sackler Institute for Nutrition ...
    ... work in protecting the lives and livelihoods of some of ... national award. At the Times Higher Education awards ceremony ... School of Planning, Architecture and Civil Engineering received the Outstanding ... recognises the team,s work in tackling the world,s worst case ...
    Cached Biology News:U of I scientists develop tool to trace metabolism of cancer-fighting tomato compounds 2Super-sized world: Conference addresses global obesity epidemic, explores policies, interventions 2Queen's life-saving research wins education 'Oscar' 2
    Protein YIPF6 (YIP1 family member 6). [Source:Uniprot/SWISSPROT;Acc:Q96EC8] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
    Bovine Calf Serum...
    ... is designed to deparaffinize and perform Heat ... paraffin-embedded tissue sections mounted on glass microscope ... paraffin at the high temperature used in ... of the paraffin by detergent. Formaldehyde fixation ...
    Chicken polyclonal to ytzF ( Abpromise for all tested applications). Antigen: Full length protein...
    Biology Products: